Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00460 SIHUAN PHARM
RTNominal down0.530 -0.040 (-7.018%)
Others

29/05/2019 09:00

Sihuan Pharm (00460) gets drug clinical trial approval

[ET Net News Agency, 29 May 2019] Sihuan Pharmaceutical Holdings Group Ltd. (00460)
said that the third generation of EGFR inhibitor XZP-5809 (the new drug), a Category 1
innovative drug developed by the group, has been granted drug clinical trial approval by
the National Medical Products Administration of the PRC.
The new drug is a novel third-generation epithelial growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI) that has strong targeting capability. It can be taken orally.
It features innovative structure, established mechanism and irreversible binding to EGFR.
(RC)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.